GCP
CTXR icon

GSA Capital Partners’s Citius Pharmaceuticals CTXR Stock Holding History

GSA Capital Partners’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,940
Closed -$136K – 1561
2023
Q3 		$136K Sell
7,940
-7,024
-47% -$167K 0.01% 1358
2023
Q2 		$449K Sell
14,964
-3,138
-17% -$103K 0.04% 811
2023
Q1 		$529K Sell
18,102
-1,849
-9% -$53.3K 0.05% 674
2022
Q4 		$394K Buy
19,951
+14,295
+253% +$390K 0.05% 751
2022
Q3 		$171K Buy
+5,656
New +$155K 0.02% 1275
2021
Q3 		– Sell
-1,786
Closed -$155K – 1498
2021
Q2 		$155K Sell
1,786
-513
-22% -$30.8K 0.02% 1216
2021
Q1 		$102K Buy
2,299
+946
+70% +$37.7K 0.02% 1000
2020
Q4 		$35K Buy
+1,353
New +$35.3K 0.01% 1144

Other funds holding CTXR

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return